BR 14

Drug Profile

BR 14

Alternative Names: BR-14

Latest Information Update: 22 Aug 2007

Price : $50

At a glance

  • Originator Bracco
  • Developer Bracco; University of Virginia
  • Class Contrast media; Fluorocarbons; Phospholipids
  • Mechanism of Action Ultrasonography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Coronary disorders; Liver disorders

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 22 Aug 2007 Discontinued - Phase-II for Liver disorders(diagnosis) in Germany (unspecified route)
  • 22 Aug 2007 Discontinued - Preclinical for Coronary disorders (diagnosis) in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top